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Abstract
Background: The aims of this study were to determine the accuracy of concurrent core needle biopsy (CNB) and
fine needle aspiration biopsy (FNAB) for breast lesions and to estimate the false-negative rate using the two
methods combined.
Methods: Over a seven-year period, 2053 patients with sonographically detectable breast lesions underwent
concurrent ultrasound-guided CNB and FNAB. The sonographic and histopathological findings were classified into
four categories: benign, indeterminate, suspicious, and malignant. The histopathological findings were compared
with the definitive excision pathology results. Patients with benign core biopsies underwent a detailed review to
determine the false-negative rate. The correlations between the ultrasonography, FNAB, and CNB were determined.
Results: Eight hundred eighty patients were diagnosed with malignant disease, and of these, 23 (2.5%) diagnoses
were found to be false-negative after core biopsy. After an intensive review of discordant FNAB results, the final
false-negative rate was reduced to 1.1% (p-value = 0.025). The kappa coefficients for correlations between methods
were 0.304 (p-value < 0.0001) for ultrasound and FNAB, 0.254 (p-value < 0.0001) for ultrasound and CNB, and 0.726
(p-value < 0.0001) for FNAB and CNB.
Conclusions: Concurrent CNB and FNAB under ultrasound guidance can provide accurate preoperative diagnosis
of breast lesions and provide important information for appropriate treatment. Identification of discordant results
using careful radiological-histopathological correlation can reduce the false-negative rate.
Background
Breast cancer has become a serious threat to women’s
health in Taiwan over recent decades. Breast cancer
ranks fourth among the top 10 causes of death from
cancer in women, and the death rate has increased from
5 to 12.8 per 100,000 population in the past two decades
(data from the Bureau of Health Promotion, Department
of Health, Taiwan; http://www.doh.gov.tw/statistic/data).
Because of this increase in the death rate, screening has
become more important in health care in Taiwan, and
screening programs with mammography and ultrasound
(US) are used routinely. However, as in several Asian
countries, Taiwanese women have smaller breasts and
denser breast tissue than do Western women,[1,2] and
this can cause false-negative findings on mammography.
Breast US is an excellent diagnostic method for effi-
ciently detecting breast tumors in dense breast tissue
[3-5].
Breast lesions detected in a screening US should be
diagnosed histopathologically because any misdiagnosis
can delay treatment of the cancer. Minimizing the num-
ber of unnecessary surgeries is essential in the diagnosis
and treatment of breast tumors. Three main diagnostic
procedures are used in the pathological examination of
suspicious breast lesions: fine needle aspiration biopsy
(FNAB), core needle biopsy (CNB), and surgical open
biopsy. FNAB and CNB are minimally invasive proce-
dures that can be performed on an outpatient basis[6,7].
The diagnostic accuracies of CNB and FNAB have
been compared. FNAB is a relevant test, especially in
combination with palpation and imaging findings[8-10].
Compared with histological evaluation, CNB is generally
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results acquired by FNAB,[11-15] especially for lesions
highly suspected of being malignant. However, a CNB
can produce false-negative results because of missam-
pling or technical failure. Both FNAB and CNB have a
specificity approaching 100% in the presence of carci-
noma, but their sensitivities range between 80% and
97%. The overall sensitivity may increase when the tests
are combined[6,7,14,15,17].
In this investigation, we analyzed data derived from a
combination of FNAB and CNB under US guidance.
The objectives of this study were to confirm the diag-
nostic accuracy of concurrent US-guided FNAB and
CNB and to analyze the methodology to identify and
reduce the rate of false-negative diagnoses.
Methods
Study population
From April 2000 to June 2007, the study population of
women with breast abnormalities who presented with
ultrasonically visible lesions was evaluated at National
Cheng Kung University Hospital, Tainan, Taiwan, using
US-guided FNAB and CNB. A total of 2053 patients
(age range, 12-102 years; mean age, 44.8 years) were
identified. No initial biopsies by surgical excision,
stereotactic biopsy, or any other studies of these lesions
were performed before the US-guided biopsies. Patients
with lesions not clearly visualized on US were excluded
from this study. Ethical approval was provided by
Human Experiment and Ethics committee of the
National Cheng Kung University Hospital (ER-99-074).
C o n c u r r e n tU S - g u i d e dC N Ba n dF N A Bw e r eu s e dt o
evaluate all sonographically visible lesions and were per-
formed in the supine position with the arm elevated,
using a high-resolution 10-14-MHz linear array transdu-
cer with adjustable puncture and biopsy guides (Falcon
Premium 2101, B-K Medical’s, Herlev, Denmark). All
procedures were performed under local anesthesia via
a ni n j e c t i o no f5c co f1 %l i d o c a i n ei n t ot h es k i na n d
subcutaneous tissue, and around the tumor. For FNAB,
the specimen was taken with at least 10 passes without
needle withdrawal and under constant negative pressure.
The cytology was checked immediately under a micro-
scope in the outpatient clinic to ensure that examinable
cells were obtained. For CNB, a 14-gauge automated
needle device with a 22 mm throw biopsy gun (Bard-
Magnum Biopsy Instrument, Covington, GA, USA) was
used. The needle was placed at the edge of the lesion in
the prefiring position, and the 22 mm core needle throw
was executed. The passage of the needle across the
index lesion was confirmed under direct visualization
with postfire US images. At least five specimens were
obtained from each lesion. Specimens were placed in
formalin and then submitted for histopathological
evaluation; the number of samples was dependent on
the lesion size, consistency, and ultrasonographic visibi-
lity. Patients with discordance between the core biopsy,
fine needle biopsy, and US findings were reviewed, and
if necessary, another biopsy or further excision was
performed.
The records of all pathologic breast reports were col-
lected and classified under the following categories[18].
B: Benign
I: Benign, but uncertain malignant potential
S: Suspicious of malignancy
M: Malignant
The findings of all breast US examinations were classi-
fied after the modification according to American Col-
lege of Radiology Breast Imaging Reporting and Data
System Atlas for Ultrasound[19] as follows.
B: Benign (BI-RADS II)
I: Probably benign findings (BI-RADS III)
S: Suspicion of malignancy (BI-RADS IV)
M: Highly suggestive of malignancy (BI-RADS V)
For patients with lesions with a benign finding after
the rebiopsy, a sonography follow-up at 6 months was
recommended. For evaluation of false-negative cases, the
case series were reviewed through linkage with the
National Cancer Registry of Taiwan.
Statistical analysis
After tabulation of the data, the specificity, sensitivity,
negative and positive predictive values, false-negative
rate, false-positive rate, and accuracy were determined
for the types of lesion to calculate whether the concur-
rent CNB and FNAC results agreed with the histopatho-
logical findings of the final excisional biopsy, surgery, or
clinical follow-up. Chi-squared test assessed paired
observation on two variables, which independent of each
other. Kappa coefficient measures the agreement
between the binary variable. All p-values were two-
tailed, with p=0.05 or lower considered significant. Sta-
tistical analysis was performed using SPSS for Windows,
version 13.0 (Chicago, IL).
Results
CNB and FNAB under US guidance were performed
concurrently to assess the breast lesions by ascertaining
a histological diagnosis. A total of 2053 CNB and FNAB
were performed. Of these, 880 patients were diagnosed
with malignant disease. On US, the average size of the
lesion was 16.7 mm (median 13 mm; range 4-150 mm).
The sensitivity of CNB and FNAB under US guidance
to identify infiltrating breast lesions was 98% and 95%,
and the specificity was 99% and 86%, respectively. The
correlation between US and FNAB was 306.775
(p < 0.0001) on the chi-squared test, and the kappa
coefficient was 0.304 (p < 0.0001). The sensitivity and
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positive predictive value was 86.12%, and the negative
p r e d i c t i v ev a l u ew a s7 3 . 7 %( T a b l e1 ) .T h ec o r r e l a t i o n
between US and CNB was 289.732 (p < 0.0001) on the
chi-squared test, and the kappa coefficient was 0.254
(p < 0.0001). The sensitivity and specificity were 23.3%
and 99.66%, respectively. The positive predictive value
was 98.09%, and the negative predictive value was
63.39% (Table 2). The correlation between FNAB and
CNB was 1137.806 (p < 0.0001) on the chi-squared test,
and the kappa coefficient was 0.726 (p < 0.0001). The
sensitivity and specificity were 72.61% and 97.78%,
respectively. The positive predictive value was 96.09%,
and the negative predictive value was 82.64% (Table 3).
Clinical features of false-negative CNB findings
Overall, 23 patients had an initial benign CNB and a sub-
sequent diagnosis of malignancy, giving a false-negative
rate of 2.5%. The distribution of the pathology of
these cases was as follows: intraductal papilloma (n = 6),
fibrocystic change (n = 5), atypical ductal hyperplasia
(n = 4), fibrous mastopathy (n = 2), papillary lesion
(n = 1), sclerosing adenosis (n = 1), lactating adenosis
(n = 1), atypical cell (n = 1), chronic inflammation (n = 1),
and other (n = 1) (Table 4).
Correlation between the FNAB and CNB findings
In 13 of the 23 false-negative cases, malignancy was
shown in the FNAB (adenocarcinoma in patients 1, 4-7,
9, 12-14, 16, 19, 20, and 22) (Table 4). Using this
Table 1 Correlation between ultrasound and FNAB
FNAB Total
MB , I , S
Ultrasound M 180 29 209
B, I, S 485 1359 1844
Total 665 1388 2053
Pearson chi-squared p-value Kappa coefficient p-value
306.775 < 0.0001 0.304 < 0.0001
Sensitivity 0.2707 Positive predictive value 0.8612
Specificity 0.9791 Negative predictive value 0.7370
B: benign, I: indeterminate, S: suspicious, M: malignant
Table 2 Correlation between ultrasound and CNB
Core biopsy Total
MB , I , S
Ultrasound M 205 4 209
B, I, S 675 1169 1844
Total 880 1173 2053
Pearson chi-squared p-value Kappa coefficient p-value
289.732 < 0.0001 0.254 < 0.0001
Sensitivity 0.2330 Positive predictive value 0.9809
Specificity 0.9966 Negative predictive value 0.6339
B: benign, I: indeterminate, S: suspicious, M: malignant
Table 3 Correlation between FNAB and CNB
Core biopsy Total
MB , I , S
FNAB M 639 26 665
B, I, S 241 1147 1388
Total 880 1173 2053
Pearson chi-squared p-value Kappa coefficient p-value
1137.806 < 0.0001 0.726 < 0.0001
Sensitivity 0.7261 Positive predictive value 0.9609
Specificity 0.9778 Negative predictive value 0.8264
B: benign, I: indeterminate, S: suspicious, M: malignant
Table 4 Distribution of the cytological and pathological
results from the 23 false-negative cases
Patient
Nr.
U FNAB U/F CNB Final Pathology
1 S M SM ADH DCIS *
2 S S SS Papilloma IDC
3 I I II Fibrocystic change DCIS
4 B M BM Fibrocystic change IDC *
5 S M SM ADH Apocrine CA *
6 I M IM Fibroadipose tissue IDC *
7 M M MM Lactating adenosis IDC *
8 I I II Papilloma DCIS
9 I M IM Papilloma IPC *
10 I I II Papilloma IDC
11 S M SM Atypical cell IDC
12 S M SM Fibrocystic change IDC *
13 S M SM Sclerosing adenosis IDC *
14 S M SM Chronic inflammation IDC *
15 M I MI Fibrocystic change IDC
16 S M SM ADH IDC *
17 I I II Papilloma IDC
18 I I II Papilloma DCIS
19 I M IM Fibrous mastopathy DCIS *
20 I M IM No evidence of
malignancy
Mucinous
carcinoma
*
21 S M SM ADH DCIS
22 S M SM Papillary lesion Mucinous CA *
23 I I II Fibrocystic change IDC
* Cases detected by fine needle aspiration biopsy
U: Ultrasound
U/F: Ultrasound/fine needle aspiration biopsy
B: Benign, I: Benign, but uncertain malignant potential, S: Suspicious of
malignancy, M: Malignant, ADH: atypical ductal hyperplasia, DCIS: ductal
carcinoma in situ, IDC: invasive ductal carcinoma, IPC: invasive papillary
carcinoma
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reduced to 10, which produced a false-negative rate of
1.1%.
Compared with the rate of 2.5% obtained by CNB
only, concurrent examination with CNB and FNAB
reduced the false-negative rate by 44% (2.5% to 1.1%,
p = 0.025).
In these 23 false-negative cases, discordance was
recognized immediately in nine because the CNB diag-
nosis was either papilloma (patients 2, 8, 10, 17, and 18)
or atypia (patient 11), and there was a malignant
appearance in one patient on sonography (patient 15),
which required an open biopsy. In two cases (patients 3
and 21), microcalcification was recognized on mammo-
graphy one year later, and patient 23 showed progres-
sion at the annual follow-up.
Discussion
Accurate preoperative assessment of breast lesions is
crucial for treatment planning. In particular, image-
guided biopsy has become an established technique.
Information on the best biopsy modality to secure a
diagnosis of breast lesions is controversial. CNB has
been shown to be an excellent tool when working with
true tissue specimens because it permits the evaluation
of both the architectural and cytological patterns. The
diagnostic accuracy of routine paraffin-embedded CNB
samples has been verified since the early 1990s, and in
their review article, Usami et al reported high concor-
dance between the diagnoses from CNB and surgical
biopsy[20]. The study by Dillon et al of 2427 core biop-
sies taken using three different CNB modalities had an
overall false-negative rate of 6.1%. However, US-guided
CNB showed the lowest false-negative rate of 1.7%[21].
The accuracy of CNB is associated with the number of
CNBs taken. In a prospective study of FNAC and CNB
in the diagnosis of breast cancer in 143 patients with a
palpable lump measuring > 2 cm,[22] four core biopsy
specimens were taken with a 14-gauge 10 cm biopsy
needle using an automated spring-loaded device. The
sensitivity of CNB increased with the number of cores
taken (one core, 76.2%; two cores, 80.9%; three cores,
89.2%; four cores, 95.2%)[6]. To ensure accuracy, at least
five cores were taken from each of our patients.
FNAB is a simple, quick, and relatively painless proce-
dure. However, the false-negative rate in the presence of
cancer is 6-11%[8,23]. Factors that may influence these
results include the experience of the clinician and
pathologist, and the size and histological type of the
tumor[7,24]. Inadequate sampling is a contributory fac-
tor to the reduced sensitivity of cytology. This can be
improved by instant cytodiagnosis after sampling in the
outpatient clinic, which can also confirm the presence
of examinable cells. If the examined cells are absent, the
sampling will repeat immediately in the outpatient
clinic. Nevertheless, the reading of the CNB slides is
only possible after formalin fixation by the pathologist.
For the diagnosis of sonographically detectable breast
lesions, US-guided FNAB was performed as the initial
sampling method, and only for uncertain lesions, a com-
plementary CNB was performed at our facility. This
study provides data on US-guided biopsy, particularly in
relation to the proportion of breast cancer cases in the
study population. US-guided techniques are performed
in real time, and the direct visualization of needle place-
ment with US allows the accuracy of the sampling to be
assessed. The procedure time is also shorter. Therefore,
US-guided biopsies have considerable advantages over
stereotactic techniques. US-guided biopsy causes less
patient discomfort compared with a stereotactic-guided
biopsy because the patient is in a prone position, and it
does not involve ionizing radiation and is less expensive
than stereotactic techniques[8,25-27]. False-negative
rates of 0.6-22.2% have been reported [11,22,26,28-46].
Only a few studies have been published on sonographic
guidance [26,28,32,43,46]. To our knowledge, our study
involves one of the largest sample sizes studied to
investigate US-guided biopsy and demonstrates that the
combination of FNAB and CNB is accurate with a false-
negative rate of 1.1%.
A false-negative diagnosis may delay the treatment of
breast cancer. The analysis by Dillon et al of the man-
agement and outcome of patients with false-negative
cores showed that reviewing the radiological, clinical,
and pathological results after the biopsy reduces the
delay in the cancer diagnosis to less than one month
[21]. US and clinical findings were found to raise the
level of suspicion in most of these cases, and FNAB can
help the clinician recognize suspicious lesions. In 13 of
the 23 patients with false-negative biopsies in our study,
it was primarily the FNAB findings that prompted
further investigation. This demonstrates a benefit of
FNAB because it decreased the false-negative rate by
44% in patients who had this procedure. Combining
CNB and FNAB techniques improves the sensitivity of
the diagnostic procedure and is supported by other stu-
dies[7,13,15,17,47].
FNAB and CNB are complementary in the accurate
diagnosis of breast cancer. There is a small risk of mis-
diagnosis, which was shown by the need for an open
surgical approach in nine patients. Concurrent CNB and
FNAB as routine assessments could have reduced the
false-negative rate in our study from 2.5% (23 of 903) to
1.1% (10 of 903). Thirteen invasive cancers were found
by FNAB after being proved by open biopsy despite a
benign diagnosis after CNB. Because the cytological
finding did not agree with the suspicious FNAB results,
13 patients were shown to have invasive cancers. After
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would have had a false-negative diagnosis and resulted
in the subsequent suboptimal treatment of patients. For-
tunately, one of these lesions was removed at the
patient’s request. Therefore, if a discordant benign lesion
in a core biopsy is recognized promptly by FNAB, a re-
biopsy is warranted, so that a false-negative diagnosis
can be identified and prevented. To identify the discor-
dance between imaging, FNAB, and CNB, the breast
specialist must be familiar with the sonographic features
and the histopathological details, and be able to corre-
late these data. Our classification using four categories
can simplify the diagnosis and thus improve the detec-
tion of false-negative cases.
High-risk lesions that have uncertain malignant poten-
tial or are suspicious for malignancy, such as atypical
ductal hyperplasia, papillary lesions, or fibrocystic
changes with atypical features, can cause the underesti-
mation of carcinoma [48-53]. Some authors have sug-
gested using a second biopsy or open biopsy in cases of
imaging-histological discordance[54,55]. There is a lack
of clarity regarding the optimal management of these
lesions. Our study shows that FNAB might reduce the
need for an unnecessary open biopsy of these lesions.
However, papillary lesions can cause underestimation of
breast carcinoma[56]. In some institutions, surgical exci-
sion is performed for papillary lesions[57-60]. In a
review of 57 patients with different papillary subtypes,
Sydnor showed an incidence of carcinoma in benign
papilloma of 3% compared with 67% for atypical papil-
loma[61]. This demonstrates the wide spectrum of
papillary lesions and the indications for surgical
excision. Papillary lesions tend to present with intrale-
sional heterogeneity, and there is a risk of concurrent or
subsequent malignancy.
Conclusion
This study has demonstrated that concurrent US-guided
CNB and fine needle biopsy are accurate for the histologi-
cal diagnosis of breast tumors. The combination of histo-
pathological and radiological findings can provide
important information for the prompt recognition of the
discordant results in the one-stop breast outpatient clinic.
Using a combined US, FNAB, and CNB assessment and
review could minimize the delay in the diagnosis of breast
cancer in women with false-negative core biopsies.
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